A phase II multicentre randomised, parallel group, double-blind, placebo-controlled study of ZD1839 (Iressa) (250mg tablet) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naive patients with advanced (stage IIIB or IV) non-small cell lung cancer and poor performance status

Trial Profile

A phase II multicentre randomised, parallel group, double-blind, placebo-controlled study of ZD1839 (Iressa) (250mg tablet) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naive patients with advanced (stage IIIB or IV) non-small cell lung cancer and poor performance status

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms INSTEP
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 10 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 18 Dec 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top